德拉沙星治疗急性细菌性皮肤及皮肤结构感染:III期疗效数据汇总分析
该汇总分析纳入2项多中心随机双盲III期试验的1510例急性细菌性皮肤及皮肤结构感染成人患者,比较德拉沙星(静脉/口服)与万古霉素/氨曲南的疗效。结果显示德拉沙星在主要终点客观缓解率上非劣于对照方案(81.3% vs 80.7%,治疗差异0.8%,95%CI -3.2%至4.7),亚组及随访结果一致,耐受性相似。
要点
- 德拉沙星单药(静脉/口服)治疗ABSSSI非劣于万古霉素/氨曲南联合方案。
- 主要终点客观缓解率:德拉沙星81.3%,对照80.7%,治疗差异0.8%(95%CI -3.2%至4.7)。
- MRSA清除率在随访时两组相当(98.1% vs 98.0%),不良事件频率相似。
核心结论
- 静脉/口服德拉沙星固定剂量单药治疗在每项III期研究及汇总分析中均非劣于静脉万古霉素/氨曲南联合治疗,且耐受性良好,不受终点或分析人群影响。
研究设计与样本
- 汇总2项多中心、随机、双盲III期试验,共1510例成人ABSSSI患者;万古霉素组每12小时接受15 mg/kg加1-2 g氨曲南,德拉沙星组研究302每12小时静脉300 mg,研究303静脉300 mg每12小时用3天后盲法转为口服450 mg每12小时。
主要发现
- 意向治疗分析中,客观缓解率德拉沙星组81.3%,对照组80.7%,平均治疗差异0.8%(95%CI -3.2%至4.7)。
- 研究者评估的成功率在随访(第14±1天)为84.7% vs 84.1%,晚期随访(第21-28天)为82.0% vs 81.7%。
- 随访时MRSA清除率德拉沙星组98.1%,对照组98.0%;两组治疗中出现的不良事件频率相似。
关键数值与推荐
- 主要终点客观缓解定义为原发感染部位红斑面积扩展在48至72小时(±2小时)内减少≥20%,且无临床失败。
临床怎么用
- 对于ABSSSI成人患者,德拉沙星可作为万古霉素/氨曲南联合方案的替代选择,覆盖革兰阳性(包括MRSA)和革兰阴性菌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Delafloxacin is an oral or intravenous (IV) antibiotic indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including both gram-positive (including methicillin-resistant Staphylococcus aureus [MRSA]) and gram-negative organisms. Chemically distinct from other quinolones, delafloxacin exhibits enhanced potency, particularly against gram-positive pathogens. The integration of efficacy data across the Phase III ABSSSI studies is presented here and allows for additional examination of results across subgroups. METHODS: Results of 2 multicenter, randomized, double-blind trials of 1510 adults with ABSSSI were pooled for this analysis. Subjects in the vancomycin arm received 15 mg/kg, plus 1-2 g of aztreonam every 12 hours. Delafloxacin was dosed at 300 mg IV every 12 hours in Study 302; dosing in Study 303 was 300 mg IV every 12 hours for 3 days, with a mandatory, blinded switch to delafloxacin at 450 mg orally every 12 hours. The primary endpoint was objective response (OR), defined as a ≥20% reduction of lesion spread of erythema area at the primary infection site at 48 to 72 hours (±2 hours), in the absence of clinical failure. Investigator-assessed response, based on the resolution of signs and symptoms at follow-up (FU; Day 14 ± 1) and late follow-up (LFU; Day 21- 28), were secondary endpoints. RESULTS: In the intent-to-treat analysis set, the OR was 81.3% in the delafloxacin arm and 80.7% in the comparator arm (mean treatment difference 0.8%, 95% confidence interval -3.2% to 4.7). Results for OR in the defined subgroups showed delafloxacin to be comparable to vancomycin/aztreonam. Investigator-assessed success was similar at FU (84.7% versus 84.1%) and LFU (82.0% versus 81.7%). Delafloxacin was comparable to vancomycin/aztreonam in the eradication of MRSA, at 98.1% versus 98.0%, respectively, at FU. The frequencies of treatment-emergent adverse events between the groups were similar. CONCLUSIONS: Overall, IV/oral delafloxacin fixed-dose monotherapy was non-inferior to IV vancomycin/aztreonam combination therapy and was well tolerated in each Phase III study, as well as in the pooled analysis, regardless of endpoint or analysis population.
引用
- Giordano PA, Pogue JM, Cammarata S, et al. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis. 2019. PMID: 30957167. doi:10.1093/cid/ciz006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。